Nebraska Advocates Celebrate DOJ Downgrade of Medical Cannabis
The DOJ medical cannabis Schedule III reclassification marks a pivotal federal policy shift. This change removes major barriers to cannabis research, enabling new clinical trials. Nebraska advocates are optimistic about the potential clinical benefits…
U.S. Department of Justice Issues Final Order Rescheduling Medical Cannabis
The final order rescheduling medical cannabis to Schedule III marks a pivotal federal policy shift. This change removes longstanding barriers to clinical research. It enables FDA-approved studies and standardized trials to advance cannabis medicine.
Cocaine and Cannabis Sold in High Street Mini-Marts – BBC Undercover Filming
Unregulated cannabis sales patient safety is a critical concern due to the lack of quality control in illegal products. These products sold in mini-marts bypass safety testing and labeling requirements. Clinicians must understand the risks associated…
What to know about Trump’s reclassification of state-licensed medical marijuana – The Hill
Trump medical marijuana reclassification could transform clinical practice by removing Schedule I barriers. This change allows physicians to prescribe cannabis and expands research opportunities. Patients and providers should stay informed about these…
Justice Department Reclassifies State-Licensed Medical Marijuana as Less Dangerous
The Justice Department medical marijuana reclassification marks a significant federal policy shift. This change improves patient access and supports clinical research. It also maintains important medical oversight for state-licensed cannabis programs.
Federal Reclassification of State-Licensed Medical Marijuana in 2026
The 2026 cannabis federal reclassification marks a pivotal shift for medical marijuana. This change from Schedule I to Schedule III will expand research and prescribing options. Patients and providers should stay informed about evolving federal policies.
White House Signals Imminent Cannabis Policy Announcements
The White House cannabis policy announcements are expected to influence patient access and clinical practice. Federal changes in cannabis policy can alter legal protections and insurance coverage. Clinicians should monitor these updates closely for their…
Webinar – Social Equity Policies in Adult-Use Cannabis Legalization
Social equity cannabis policies are crucial in shaping adult-use legalization frameworks. These policies influence patient access to regulated cannabis medicine and market structures. Clinicians must understand these policies to guide patients…
Trump Administration Ready To Move Ahead On Marijuana Rescheduling
The Trump administration cannabis rescheduling update signals a major shift in federal policy. This change could affect clinical practice by altering prescribing protocols and insurance coverage. Healthcare providers should monitor these developments…
New Congressional Bill Would Let State Agencies Provide Marijuana for Research, Backed by $150M
The new congressional bill marijuana research initiative proposes allowing state-licensed agencies to supply cannabis for studies. This could break the federal monopoly and accelerate clinical data generation. Expanding access is crucial for…